JP2023550652A5 - - Google Patents
Info
- Publication number
- JP2023550652A5 JP2023550652A5 JP2023531555A JP2023531555A JP2023550652A5 JP 2023550652 A5 JP2023550652 A5 JP 2023550652A5 JP 2023531555 A JP2023531555 A JP 2023531555A JP 2023531555 A JP2023531555 A JP 2023531555A JP 2023550652 A5 JP2023550652 A5 JP 2023550652A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- species
- composition
- compared
- reduce
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118639P | 2020-11-25 | 2020-11-25 | |
| US63/118,639 | 2020-11-25 | ||
| PCT/US2021/060878 WO2022115646A1 (en) | 2020-11-25 | 2021-11-24 | Designed bacterial compositions for treating graft-versus-host-disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550652A JP2023550652A (ja) | 2023-12-04 |
| JP2023550652A5 true JP2023550652A5 (https=) | 2024-12-03 |
Family
ID=81756137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531555A Pending JP2023550652A (ja) | 2020-11-25 | 2021-11-24 | 移植片対宿主病を処置するための設計された細菌組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240000859A1 (https=) |
| EP (1) | EP4250932A4 (https=) |
| JP (1) | JP2023550652A (https=) |
| KR (1) | KR20230124601A (https=) |
| CN (1) | CN116709924A (https=) |
| AU (1) | AU2021388169A1 (https=) |
| CA (1) | CA3199153A1 (https=) |
| MX (1) | MX2023006146A (https=) |
| WO (1) | WO2022115646A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240226191A1 (en) * | 2021-05-10 | 2024-07-11 | Microba Ip Pty Ltd | Compositions and methods for treating disease |
| CN114788837B (zh) * | 2022-06-07 | 2023-09-05 | 青岛东海药业有限公司 | 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用 |
| EP4687930A2 (en) * | 2023-01-30 | 2026-02-11 | Seres Therapeutics, Inc. | Use of designed bacterial compositions for infection treatment |
| GB2627012A (en) * | 2023-02-13 | 2024-08-14 | Acad Medisch Ct | Predictive biomarker of neonatal E.coli mediated sepsis |
| AU2024327567A1 (en) * | 2023-08-22 | 2026-01-08 | Danisco Usa Inc. | Methods and compositions for immune system regulation |
| CN117907608B (zh) * | 2024-03-19 | 2024-05-24 | 苏州和锐生物科技有限公司 | 一种Claudin2蛋白的检测方法及其相关产品和应用 |
| CN118987051A (zh) * | 2024-09-13 | 2024-11-22 | 南方医科大学南方医院 | 粪副拟杆菌在制备治疗移植物抗宿主病药物中的应用 |
| CN119055685A (zh) * | 2024-09-13 | 2024-12-03 | 南方医科大学南方医院 | 粪副拟杆菌在制备分离移植物抗白血病效应与移植物抗宿主病药物中的应用 |
| CN120700173B (zh) * | 2025-09-01 | 2026-01-02 | 华中科技大学同济医学院附属协和医院 | 甲状腺相关眼病的微生物标志物、产品及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| SG11201503966PA (en) * | 2012-11-23 | 2015-06-29 | Seres Health Inc | Synergistic bacterial compositions and methods of production and use thereof |
| JP2016509003A (ja) * | 2013-02-04 | 2016-03-24 | セレス セラピューティクス インコーポレイテッド | 組成物および方法 |
| US10973861B2 (en) * | 2013-02-04 | 2021-04-13 | Seres Therapeutics, Inc. | Compositions and methods |
| WO2014145958A2 (en) * | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| CN105979952B (zh) * | 2013-11-25 | 2022-04-08 | 赛里斯治疗公司 | 协同细菌组合物以及其制造方法和用途 |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| PL3380108T3 (pl) * | 2015-11-24 | 2023-03-27 | Seres Therapeutics, Inc. | Zaprojektowane kompozycje bakteryjne |
| WO2017091753A1 (en) * | 2015-11-25 | 2017-06-01 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization |
| EP3429604A1 (en) * | 2016-03-14 | 2019-01-23 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US9999641B2 (en) * | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| JP2020530494A (ja) * | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 健康な腸バリアを維持及び回復するための組成物及び方法 |
| AU2018313765A1 (en) * | 2017-08-07 | 2020-02-27 | Finch Therapeutics, Inc. | Compositions and methods for decolonizing antibotic-resistant bacteria in the gut |
| EP3668527A1 (en) * | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| AU2019217041B2 (en) * | 2018-02-09 | 2022-09-15 | Keio University | Compositions and methods for the induction of CD8+ T-cells |
-
2021
- 2021-11-24 WO PCT/US2021/060878 patent/WO2022115646A1/en not_active Ceased
- 2021-11-24 JP JP2023531555A patent/JP2023550652A/ja active Pending
- 2021-11-24 AU AU2021388169A patent/AU2021388169A1/en active Pending
- 2021-11-24 MX MX2023006146A patent/MX2023006146A/es unknown
- 2021-11-24 US US18/254,449 patent/US20240000859A1/en active Pending
- 2021-11-24 KR KR1020237021388A patent/KR20230124601A/ko active Pending
- 2021-11-24 CA CA3199153A patent/CA3199153A1/en active Pending
- 2021-11-24 EP EP21899146.1A patent/EP4250932A4/en active Pending
- 2021-11-24 CN CN202180090783.5A patent/CN116709924A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023550652A5 (https=) | ||
| Liu et al. | The microbiome in inflammatory bowel diseases: from pathogenesis to therapy | |
| Eeckhaut et al. | Butyricicoccus pullicaecorum in inflammatory bowel disease | |
| Liu et al. | Lactobacillus casei LH23 modulates the immune response and ameliorates DSS-induced colitis via suppressing JNK/p-38 signal pathways and enhancing histone H3K9 acetylation | |
| Shen et al. | Bugging inflammation: role of the gut microbiota | |
| Zhang et al. | Lactobacillus rhamnosus GG affects microbiota and suppresses autophagy in the intestines of pigs challenged with Salmonella Infantis | |
| Li et al. | Current status of probiotics as supplements in the prevention and treatment of infectious diseases | |
| JP5948323B2 (ja) | Ｌ．ジョンソニイＬａ１、Ｂ．ロングムＮＣＣ２７０５及び免疫障害 | |
| Möndel et al. | Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans | |
| JP2020530493A5 (https=) | ||
| Al-Fakhrany et al. | Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents | |
| Alexandre et al. | Probiotics: a new way to fight bacterial pulmonary infections? | |
| Döring et al. | BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs | |
| Elshaghabee et al. | Mitigation of antibiotic resistance using probiotics, prebiotics and synbiotics. A review | |
| Pusceddu et al. | Targeting the microbiota, from irritable bowel syndrome to mood disorders: focus on probiotics and prebiotics | |
| Cope et al. | Novel microbiome-based therapeutics for chronic rhinosinusitis | |
| WO2012142605A1 (en) | Rapid recolonization deployment agent | |
| Lê et al. | Inflammatory bowel disease therapeutic strategies by modulation of the microbiota: how and when to introduce pre-, pro-, syn-, or postbiotics? | |
| Fu et al. | Protective effect of Bacillus amyloliquefaciens against Salmonella via polarizing macrophages to M1 phenotype directly and to M2 depended on microbiota | |
| Mikov et al. | Probiotics as a promising treatment for inflammatory bowel disease | |
| Liu et al. | Alleviation of DSS-induced colitis in mice by a new-isolated Lactobacillus acidophilus C4 | |
| Rudiansyah et al. | The emerging microbiome‐based approaches to IBD therapy: from SCFAs to urolithin A | |
| Shukla et al. | Comparative analysis of antigiardial potential of heat inactivated and probiotic protein of probiotic Lactobacillus rhamnosus GG in murine giardiasis | |
| Yang et al. | Metformin alleviates liver fibrosis in mice by enriching Lactobacillus sp. MF-1 in the gut microbiota | |
| Li et al. | Changes of intestinal microbiota and microbiota-based treatments in IBD |